<div style="padding: 20px;">
    <table cellspacing="0" cellpadding="0" border="0" width="90%">
        <tbody>
            <tr valign="top">
                <td>
                    <a target="_blank" href="http://www.visioncareprofessional.com/ereader/bl/uveitis/index.html">
                        <img border="0" alt="2" style="border: solid 1px #000000" src="http://www.retinalphysician.com/esupplements/wang.jpg"></a>
                </td>
                <td>
                    <span class="style1"><span class="style13"><a target="_blank" href="http://www.visioncareprofessional.com/ereader/bl/uveitis/index.html">
                        Care of Patients with Chronic Noninfectious Posterior Uveitis</a></span><br>
                        <span class="style5"><span class="style6">Presented by:</span> <strong>Bausch + Lomb</strong></span><span
                            class="style9"><br>
                            <br>
                        </span><span class="style5"><span class="style11">For retinal physicians, there is another
                            opportunity to treat a difficult disease. This supplement is edited by a special
                            guest editor, Robert C. Wang, MD, a fellowship-trained expert in the diagnosis and
                            treatment of uveitis.</span> </span>
                        <br>
                    </span>
                </td>
            </tr>
            <tr valign="top">
                <td>
                    &nbsp;
                </td>
                <td>
                    &nbsp;
                </td>
            </tr>
            <tr valign="top">
                <td width="18%">
                    <a target="_blank" href="http://www.visioncareprofessional.com/ereader/bl/stellaris/index.html">
                        <img border="0" alt="2" style="border: solid 1px #000000" src="esupplements/BLStellarisCover.jpg"></a>
                </td>
                <td width="82%">
                    <p class="style1">
                        <span class="style13"><a target="_blank" href="http://www.visioncareprofessional.com/ereader/bl/stellaris/index.html">
                            Surgical Experiences with the Stellaris PC System</a></span><br>
                        <span class="style5"><span class="style6">Sponsored by:</span> <strong>Bausch + Lomb</strong><br>
                        </span><span class="style7">Presenters: </span><span class="style9">: Jeffrey S. Heier,
                            MD (moderator); Andrew N. Antoszyk, MD; Kevin J. Blinder, MD; Derek Y. Kunimoto,
                            MD, JD; Asheesh Tewari, MD and Kenneth J. Wald, MD<br>
                            <br>
                        </span><span class="style5"><span class="style11">This new platform gives surgeons true
                            "procedural choice" by providing advanced technology for vitreoretinal surgery and
                            cataract surgery in a single system. A roundtable of surgeons discuss their professional
                            experience with this new system. </span></span>
                        <br>
                    </p>
                </td>
            </tr>
            <tr valign="top">
                <td height="20">
                    &nbsp;
                </td>
                <td>
                    &nbsp;
                </td>
            </tr>
            <tr valign="top">
                <td width="18%">
                    <a target="_blank" href="http://www.retinalphysician.com/digsupps/bl/index.html">
                        <img border="0" alt="2" style="border: solid 1px #000000" src="esupplements/BLCover.jpg"></a>
                </td>
                <td width="82%">
                    <p class="style1">
                        <span class="style13"><a target="_blank" href="http://www.retinalphysician.com/digsupps/bl/index.html">
                            Introducing the Stellaris PC Vision Enhancement System</a></span><br>
                        <span class="style5"><span class="style6">Sponsored by:</span> <strong>Bausch + Lomb</strong><br>
                        </span><span class="style7">Presenters: </span><span class="style9">Carl C. Awh, MD;
                            David R. Chow, MD, FRCSC; Philip Ferrone, MD; Tarek Hassan, MD and Suber S. Huang,
                            MD, MBA<br>
                            <br>
                        </span><span class="style5"><span class="style11">The new combined vitrectomy and phacoemulsification
                            system is the latest innovation from Bausch + Lomb. A panel of renowned surgeons
                            present their experience with this new, innovative system. Digital supplement includes
                            videos of the presentations. </span></span>
                        <br>
                    </p>
                </td>
            </tr>
            <tr valign="top">
                <td height="20">
                    &nbsp;
                </td>
                <td>
                    &nbsp;
                </td>
            </tr>
            <tr valign="top">
                <td width="18%">
                    <a target="_blank" href="http://www.visioncareprofessional.com/ereader/genentech/1/index.html">
                        <img border="0" alt="2" src="esupplements/esupp_genentech1.jpg"></a>
                </td>
                <td width="82%">
                    <p class="style1">
                        <span class="style13"><a target="_blank" href="http://www.visioncareprofessional.com/ereader/genentech/1/index.html">
                            Streamlining Your Retina Practice</a></span><br>
                        <span class="style5"><span class="style6">Sponsored by:</span> <strong>Genentech</strong><br>
                        </span>
                        <br>
                        <span class="style11">The introduction of anti-VEGF therapy signaled a new era in retina
                            practice. Learn how busy practices across the country ensure efficient delivery
                            of this breakthrough treatment.</span>
                    </p>
                </td>
            </tr>
            <tr valign="top">
                <td height="20">
                    &nbsp;
                </td>
                <td>
                    &nbsp;
                </td>
            </tr>
            <tr valign="top">
                <td width="18%">
                    <a target="_blank" href="http://www.retinalphysician.com/esupplements/bl/1/index.html">
                        <img border="0" alt="2" src="esupplements/esupplement1_cover.jpg"></a>
                </td>
                <td width="82%">
                    <p class="style1">
                        <span class="style13"><a target="_blank" href="http://www.retinalphysician.com/esupplements/bl/1/index.html">
                            Clinical Perspectives and Considerations With Retisert&reg; (fluocinolone acetonide
                            intravitreal implant) 0.59 mg in the Management of Chronic Non-infectious Uveitis
                            of the Posterior Segment: Expertise Beyond the 3-year Follow-up Clinical Trial Data</a></span><br>
                        <span class="style5"><span class="style6">Sponsored by:</span> <strong>Bausch &amp;
                            Lomb</strong><br>
                        </span><span class="style7">Presenters: </span><span class="style9">Quan Dong Nguyen,
                            MD, MSc, Panel Chair David G. Callanan, MD Debra A. Goldstein, MD, FRCSC Dean Eliott,
                            MD Peter A. Netland, MD, PhD David G. Godfrey, MD Sunil K. Srivastava, MD<br>
                            <br>
                        </span><span class="style5"><span class="style11">An expert panel of 7 uveitis, retina,
                            and glaucoma specialists gathered in Chicago in August of 2009 to discuss the appropriate
                            indications and applications of Retisert&reg; (fluocinolone acetonide intravitreal
                            implant) 0.59 mg. These specialists have extensive experience with the diagnosis
                            and management of chronic non-infectious uveitis, the surgical placement and/or
                            reimplantation of Retisert, and the medical and surgical management of ocular adverse
                            events after implantation. In addition, two of the panel members were also investigators
                            as part of the Fluocinolone Acetonide Study Group (Drs Callanan and Goldstein).
                        </span></span>
                    </p>
                    <p class="style1">
                        <br>
                    </p>
                </td>
            </tr>
            <tr valign="top">
                <td height="20">
                    &nbsp;
                </td>
                <td>
                    &nbsp;
                </td>
            </tr>
        </tbody>
    </table>
</div>
